Press coverage about Foundation Medicine (NASDAQ:FMI) has been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Foundation Medicine earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.339789112557 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Adaptive Biotechnologies Appoints Veteran Molecular Diagnostics … – Business Wire (press release) (businesswire.com)
- Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2017 Financial Results and Conference Call (finance.yahoo.com)
- Foundation Medicine (FMI) Scheduled to Post Earnings on Tuesday (americanbankingnews.com)
- Foundation Medicine (FMI) Downgraded by BidaskClub to Hold (americanbankingnews.com)
- Insider Selling: Foundation Medicine Inc (FMI) COO Sells 23,064 Shares of Stock (americanbankingnews.com)
Shares of Foundation Medicine (NASDAQ FMI) opened at $65.60 on Thursday. Foundation Medicine has a 52 week low of $22.40 and a 52 week high of $75.20. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.03 and a current ratio of 2.24. The company has a market cap of $2,380.00, a P/E ratio of -14.68 and a beta of -0.03.
In related news, CFO Jason Ryan sold 21,726 shares of the stock in a transaction that occurred on Tuesday, December 5th. The shares were sold at an average price of $61.26, for a total value of $1,330,934.76. Following the transaction, the chief financial officer now directly owns 55,639 shares in the company, valued at $3,408,445.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Troy Cox sold 26,713 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $70.13, for a total transaction of $1,873,382.69. Following the completion of the transaction, the chief executive officer now owns 224,345 shares in the company, valued at $15,733,314.85. The disclosure for this sale can be found here. Insiders sold 228,717 shares of company stock worth $14,987,592 over the last 90 days. 2.70% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Foundation Medicine (FMI) Stock Price” was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://weekherald.com/2018/02/15/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-foundation-medicine-fmi-stock-price.html.
About Foundation Medicine
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.